Billiontoone (NASDAQ:BLLN) Insider Sells $785,760.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock in a transaction on Monday, June 8th. The shares were sold at an average price of $98.22, for a total value of $785,760.00. Following the completion of the sale, the insider directly owned 212,000 shares of the company’s stock, valued at $20,822,640. The trade was a 3.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Trading Up 1.5%

Shares of NASDAQ BLLN opened at $101.12 on Friday. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $138.70. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. The stock has a fifty day simple moving average of $88.03 and a 200-day simple moving average of $88.20. The stock has a market capitalization of $4.65 billion and a PE ratio of 183.85.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The firm had revenue of $108.39 million during the quarter, compared to analyst estimates of $95.81 million. During the same period in the previous year, the firm posted ($0.39) earnings per share. The company’s quarterly revenue was up 83.8% compared to the same quarter last year. On average, equities analysts forecast that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently commented on BLLN. Weiss Ratings cut Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 5th. JPMorgan Chase & Co. boosted their target price on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Wells Fargo & Company lowered their target price on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. BTIG Research lowered their target price on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Billiontoone presently has an average rating of “Moderate Buy” and an average price target of $125.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Adams Street Partners LLC acquired a new position in shares of Billiontoone during the 4th quarter worth about $140,063,000. Baillie Gifford & Co. acquired a new position in shares of Billiontoone during the 4th quarter worth about $103,786,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Billiontoone during the 4th quarter worth about $39,717,000. JPMorgan Chase & Co. acquired a new position in shares of Billiontoone during the 4th quarter worth about $32,078,000. Finally, Wasatch Advisors LP acquired a new position in shares of Billiontoone during the 1st quarter worth about $29,179,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.